CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety



Godói, Isabella Piassi, Lemos, Livia Lovato Pires, de Araújo, Vânia Eloisa, Bonoto, Braúlio Cesar, Godman, Brian ORCID: 0000-0001-6539-6972 and Guerra Júnior, Augusto Afonso
(2017) CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. Journal of Comparative Effectiveness Research, 6 (2). 165 - 180.

[img] Text
Accepted for publication.doc - Accepted Version

Download (990kB)

Abstract

<jats:p> Introduction: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia<jats:sup>®</jats:sup>) was the first vaccine to gain regulatory approval to try and address this problem. Aim: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. Method: Meta-analysis and systematic review. Results: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2–16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events. Conclusion: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population. </jats:p>

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 13 Jun 2017 07:28
Last Modified: 06 Sep 2021 11:37
DOI: 10.2217/cer-2016-0045
URI: https://livrepository.liverpool.ac.uk/id/eprint/3007940